Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenzilumab for severe COVID-19 in hospitalized cancer patients
ACTRN12620000844943Phase 3Withdrawn
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in coronavirus disease 2019 (COVID-19) comparing Lenzilumab with Placebo (2 arms). Primary endpoint: Time to clinical improvement or hospital discharge. Planned start Sep 2020; status: withdrawn.
02
Drugs
lenzilumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ACTRN12620000844943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000844943.